



SUNESIS

Sunesis Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

July 5, 2016

SOUTH SAN FRANCISCO, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12th at 1:00 PM Eastern Time at Le Parker Meridien New York.

A live webcast of the presentation will be available on the Sunesis website at <http://ir.sunesis.com>. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer and is currently pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older. In addition, the company is advancing its kinase-inhibitor pipeline of novel targeted therapies into the clinic.

For additional information on Sunesis, please visit <http://www.sunesis.com>.

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

Investor and Media Inquiries:

David Pitts
Argot Partners
212-600-1902

Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717

 [Primary Logo](#)

Sunesis Pharmaceuticals Inc